Evaluation of Response to Gemcitabine Plus Cisplatin-based Chemotherapy Using Positron Emission Computed Tomography for Metastatic Bladder Cancer

Overview

Journal World J Clin Cases

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2024 Jan 8

PMID 38188218

Authors

Hakan Ozturk

Inanc Karapolat

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of the present study was to examine retrospectively the contribution of Fluorodeoxyglucose positron emission tomography computed tomography (FDG-PET/CT) to the evaluation of response to first-line gemcitabine plus cisplatin-based chemotherapy in patients with metastatic bladder cancer.

Aim: To evaluate the response to Gemcitabine plus Cisplatin -based chemotherapy using FDG-PET/CT imaging in patients with metastatic bladder cancer.

Methods: Between July 2007 and April 2019, 79 patients underwent FDG-PET/CT imaging with the diagnosis of Metastatic Bladder Carcinoma (M-BCa). A total of 42 patients (38 male, 4 female) were included in the study, and all had been administered Gemcitabine plus Cisplatin-based chemotherapy. After completion of the therapy, the patients underwent a repeat FDG-PET/CT scan and the results were compared with the PET/CT findings before chemotherapy according to European Organisation for the Research and treatment of cancer criteria. Mean age was 66.1 years and standard deviation was 10.7 years (range: 41-84 years).

Results: Of the patients, seven (16.6%) were in complete remission, 17 (40.5%) were in partial remission, six (14.3%) had a stable disease, and 12 (28.6%) had a progressive disease. The overall response rate was 57.1 percent.

Conclusion: FDG-PET/CT can be considered as a successful imaging tool in evaluating response to first-line chemotherapy for metastatic bladder cancer. Anatomical and functional data obtained from PET/CT scans may be useful in the planning of secondline and thirdline chemotherapy.

References

Ploeg M, Aben K, Kiemeney L . The present and future burden of urinary bladder cancer in the world. World J Urol. 2009; 27(3):289-93. PMC: 2694323. DOI: 10.1007/s00345-009-0383-3. View

Seo Y, Kim S, Kim H, Kim C, Park S, Koh E . Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report. J Hematol Oncol. 2010; 3:4. PMC: 2818621. DOI: 10.1186/1756-8722-3-4. View

Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C . Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013; 37(3):219-25. DOI: 10.1016/j.canep.2013.02.002. View

Rosenberg J, Carroll P, Small E . Update on chemotherapy for advanced bladder cancer. J Urol. 2005; 174(1):14-20. DOI: 10.1097/01.ju.0000162039.38023.5f. View

Heidenreich A, Albers P, Classen J, Graefen M, Gschwend J, Kotzerke J . Imaging studies in metastatic urogenital cancer patients undergoing systemic therapy: recommendations of a multidisciplinary consensus meeting of the Association of Urological Oncology of the German Cancer Society. Urol Int. 2010; 85(1):1-10. DOI: 10.1159/000318985. View

Moussa M, Chakra M, Saad W, Dellis A, Papatsoris A . The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer. Urol Oncol. 2021; 39(12):833.e9-833.e17. DOI: 10.1016/j.urolonc.2021.04.027. View

Bouchelouche K, Turkbey B, Choyke P . PET/CT and MRI in Bladder Cancer. J Cancer Sci Ther. 2013; S14(1). PMC: 3587689. DOI: 10.4172/1948-5956.S14-001. View

MOERTEL C, Hanley J . The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer. 1976; 38(1):388-94. DOI: 10.1002/1097-0142(197607)38:1<388::aid-cncr2820380156>3.0.co;2-a. View

Stenzl A, Cowan N, De Santis M, Jakse G, Kuczyk M, Merseburger A . The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009; 55(4):815-25. DOI: 10.1016/j.eururo.2009.01.002. View

10.

Richters A, van Ginkel N, Meijer R, Wondergem M, Schoots I, Vis A . Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle-invasive bladder cancer: a nationwide population-based study. BJU Int. 2023; 132(4):420-427. DOI: 10.1111/bju.16091. View

11.

Drieskens O, Oyen R, van Poppel H, Vankan Y, Flamen P, Mortelmans L . FDG-PET for preoperative staging of bladder cancer. Eur J Nucl Med Mol Imaging. 2005; 32(12):1412-7. DOI: 10.1007/s00259-005-1886-9. View

12.

Morisawa N, Koyama T, Togashi K . Metastatic lymph nodes in urogenital cancers: contribution of imaging findings. Abdom Imaging. 2006; 31(5):620-9. DOI: 10.1007/s00261-005-0244-5. View

13.

van Ginkel N, van Gennep E, Oosterbaan L, Greidanus J, Boellaard T, Wondergem M . Added Clinical Value of F-FDG-PET/CT to Stage Patients With High-Risk Non-Muscle Invasive Bladder Cancer Before Radical Cystectomy. Clin Genitourin Cancer. 2023; 21(3):342-348. DOI: 10.1016/j.clgc.2023.02.004. View

14.

Lu Y, Chen J, Liang J, Wang H, Lin C, Lin W . Clinical value of FDG PET or PET/CT in urinary bladder cancer: a systemic review and meta-analysis. Eur J Radiol. 2011; 81(9):2411-6. DOI: 10.1016/j.ejrad.2011.07.018. View

15.

Sengelov L, Kamby C, von der Maase H . Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years. Eur Urol. 2001; 39(6):634-42. DOI: 10.1159/000052520. View

16.

Apolo A, Riches J, Schoder H, Akin O, Trout A, Milowsky M . Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J Clin Oncol. 2010; 28(25):3973-8. PMC: 2940395. DOI: 10.1200/JCO.2010.28.7052. View

17.

Ismaili N, Amzerin M, Flechon A . Chemotherapy in advanced bladder cancer: current status and future. J Hematol Oncol. 2011; 4:35. PMC: 3178536. DOI: 10.1186/1756-8722-4-35. View

18.

Kibel A, Dehdashti F, Katz M, Klim A, Grubb R, Humphrey P . Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J Clin Oncol. 2009; 27(26):4314-20. PMC: 4035361. DOI: 10.1200/JCO.2008.20.6722. View

19.

Bellmunt J, Albiol S, de Olano A, Pujadas J, Maroto P . Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium. Ann Oncol. 2006; 17 Suppl 5:v113-7. DOI: 10.1093/annonc/mdj964. View

20.

Sternberg C, Yagoda A, Scher H, Watson R, Ahmed T, Weiselberg L . Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J Urol. 1985; 133(3):403-7. DOI: 10.1016/s0022-5347(17)48996-8. View